---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-029097"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:38:44.352216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VYNE reports Q4/FY 2023 loss; cash $93.3M; VYN201 Phase 2b starts Q2 2024; VYN202 Phase 1a expected Q2 2024

## Summary
- Cash, cash equivalents, restricted cash and marketable securities $93.3M at Dec 31, 2023, providing runway through end of 2025.
- GAAP loss from continuing ops Q4 2023 $6.15M vs $7.76M in Q4 2022; full year $27.87M vs $33.95M (improved YoY).
- Adjusted net loss Q4 2023 $5.48M vs $8.88M; full year $25.15M vs $18.91M (wider YoY for FY).
- VYN201 Phase 2b trial in nonsegmental vitiligo to begin Q2 2024; top-line results mid-2025; gel formulation selected.
- VYN202 IND submitted Dec 2023; FDA requested additional nonclinical study; completed consistent with expectations; Phase 1a expected Q2 2024 if FDA clears.

## SEC filing metadata
- accession: 0001104659-24-029097
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465924029097/0001104659-24-029097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465924029097/tm247462d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-029097
- JSON: https://secwatch.observer/filing/0001104659-24-029097.json
- Plain text: https://secwatch.observer/filing/0001104659-24-029097.txt

## Key facts
- Earnings Releases
  VYNE Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465924029097/0001104659-24-029097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.